Xeloda (Breast cancer) Analysis and Forecasts to 2020


#28326

45pages

GlobalData

$ 2000

In Stock


GlobalDatas pharmaceuticals report, Xeloda (Breast cancer) - Analysis and Forecasts to 2020 provides Xeloda sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Xeloda including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Xeloda including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts from 2002-2020 for Xeloda in the seven major markets

Reasons to buy

 

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 GlobalData Report Guidance 7


3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 8
3.3.1 High Prevalence 9
3.3.2 Breast Cancer: Most Frequent Cancer in Women 9
3.3.3 Increasing Breast Cancer Incidence Rate 9
3.3.4 Decreasing Breast Cancer Mortality Rate 11
3.3.5 High Survival Rates of Breast Cancer 13


4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15


5 Predictive Biomarker in the Treatment of Breast Cancer 18


6 Treatment Options of Breast Cancer 20
6.1 Stage 0 Breast Cancer: Treatment Options 20
6.2 Early Stage Breast Cancer (Excluding Stage 0) 21
6.3 Metastatic Breast Cancer (MBC) 23
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 23
6.3.2 Cytotoxic Chemotherapy 25
6.3.3 Management of Patients with HER-2 Positive Patients 27


7 Xeloda 29
7.1 Introduction 29
7.2 Mechanism of Action 29
7.3 Clinical Studies 29
7.3.1 Breast Cancer Combination Therapy 29
7.3.2 Breast Cancer Monotherapy 30
7.4 Approval History of Xeloda 30
7.5 Factors Affecting Sales 31
7.5.1 Patent Expiry of Competing Drug 31
7.5.2 Absence of Gemzar, Tykerb and Omnitarg in the Third and Fourth Line of Treatment 31
7.5.3 Approval of Xeloda as an Adjuvant Therapy in Early Breast Cancer 31
7.6 Drug Risk Benefit Score 31
7.6.1 Efficacy 32
7.6.2 Safety 32
7.6.3 Compliance 32
7.6.4 Dosing Convenience 32
7.7 Intensity of Competition 32
7.8 Sales Forecast 33
7.8.1 Target Patient Pool of Xeloda 33
7.8.2 Dosing 34
7.8.3 Market Penetration 34
7.8.4 Annual Cost of Therapy 35
7.8.5 Sales Projection of Xeloda 35


8 Appendix 41
8.1 Market Definitions 41
8.2 Abbreviations 41
8.3 Research Methodology 41
8.3.1 Coverage 41
8.3.2 Secondary Research 42
8.3.3 Forecasting 42
8.3.4 Number of Patients Approved to take the Drug 42
8.3.5 Net Penetration of Drug 43
8.3.6 Net Annual Dosing 44
8.3.7 Annual Cost of Therapy 44
8.3.8 Primary Research 44
8.3.9 Expert Panels 44
8.4 Contact Us 45
8.5 Disclaimer 45
8.6 Sources 45


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Table 3: Five-Year Relative Survival Rates, By Stages 14
Table 4: Efficacy of Xeloda and docetaxel Combination vs. docetaxel Monotherapy 30
Table 5: Response Rates in Breast Cancer Monotherapy with Xeloda 30
Table 6: Approval History of Xeloda 30
Table 7: Drug Risk Benefit Score of Xeloda as a Combination Therapy 31
Table 8: Drug Risk Benefit Score of Xeloda as Monotherapy 32
Table 9: Annual Cost of Therapy of Xeloda 35
Table 10: Xeloda, Breast Cancer, Global, Sales Estimates ($m), 20022009 36
Table 11: Xeloda, Breast Cancer, Global, Sales Forecasts ($m), 20102020 36
Table 12: Xeloda, Breast Cancer, the US, Sales Estimates ($m), 20022009 37
Table 13: Xeloda, Breast Cancer, the US, Sales Forecasts ($m), 20102020 37
Table 14: Xeloda, Breast Cancer, EU, Sales Estimates ($m), 20022009 38
Table 15: Xeloda, Breast Cancer, EU, Sales Forecasts ($m), 20102020 38
Table 16: Xeloda, Breast Cancer, Japan, Sales Estimates ($m), 20032009 39
Table 17: Xeloda, Breast Cancer, Japan, Sales Forecasts ($m),20102020 39


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Top 10 Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 9
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 11
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 12: Broad Classification of Breast Cancer, By Type 15
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 14: Classification of Invasive Breast Cancer, By Stages 16
Figure 15: Classification of Invasive Breast Cancer, By Treatment 16
Figure 16: Classification of Metastatic or Advanced Breast Cancer 16
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 17
Figure 18: Classification of Locally Advanced Breast Cancer 17
Figure 19: Metastatic Breast Cancer Classification 17
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18
Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 19
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 19
Figure 23: Treatment Options, DCIS Breast Cancer 20
Figure 24: Treatment Options, LCIS Breast Cancer 21
Figure 25: Treatment Options, Stages I, II and IIIA 21
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 24
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 27
Figure 33: Drug Model Diagram of Xeloda in the US and EU 33
Figure 34: Drug Model Diagram of Xeloda in Japan 34
Figure 35: Xeloda, Breast Cancer, Global, Sales Estimates ($m), 20022020 36
Figure 36: Xeloda, Breast Cancer, the US, Sales Estimates ($m), 20022020 37
Figure 37: Xeloda, Breast Cancer, EU, Sales Estimates ($m), 20022020 38
Figure 38: Xeloda, Breast Cancer, Japan, Sales Estimates ($m), 2003-2020 39
Figure 39: Xeloda, Breast Cancer, Global, Sales Distribution by Country ($m), 2012 40
Figure 40: Drug Model Diagram 43
Figure 41: Patients Approved to take the Drug 44